SUPN · Insider Trading
Supernus Pharmaceuticals, Inc.
Every open-market purchase and sale reported by SUPN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Jonathan Rubin | SVP, Chief Medical Officer | MIXED | +387 | −$16.90K |
| 2026-08-14 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | +853 | −$37.12K |
| 2026-08-14 | Timothy C Dec | Senior Vice-President & CFO | MIXED | +646 | −$28.13K |
| 2026-08-14 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | +1,342 | −$53.93K |
| 2026-08-14 | Jack A. Khattar | President, CEO | MIXED | +17,207 | −$588.74K |
| 2026-07-31 | Jonathan Rubin | SVP, Chief Medical Officer | A | +750 deriv. | — |
| 2026-07-31 | Jack A. Khattar | President, CEO | A | +29,849 deriv. | — |
| 2026-07-31 | Timothy C Dec | Senior Vice-President & CFO | A | +1,250 deriv. | — |
| 2026-07-31 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | A | +2,500 deriv. | — |
| 2026-07-31 | Frank Mottola | SVP, Chief Tech. Ops. Officer | A | +1,650 deriv. | — |
| 2026-03-18 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | — | −$1.50M |
| 2026-03-16 | Frederick M. Hudson | Director | Sell | −5,369 | −$271.73K |
| 2026-03-16 | Jack A. Khattar | President, CEO | MIXED | −35,000 | −$1.76M |
| 2026-03-10 | Timothy C Dec | Senior Vice-President & CFO | MIXED | +3,117 | −$157.79K |
| 2026-03-10 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | +334 | −$185.20K |
| 2026-03-10 | Jack A. Khattar | President, CEO | MIXED | +22,066 | −$907.10K |
| 2026-03-10 | William Todd Horich | SVP, Commercial Operations | MIXED | −4,832 | −$672.89K |
| 2026-03-09 | Georges Gemayel | Director | MIXED | −10,882 | −$802.81K |
| 2026-03-03 | Frank Mottola | SVP, Chief Tech. Ops. Officer | A | +3,750 deriv. | — |
| 2026-03-03 | Jack A. Khattar | President, CEO | A | +38,640 deriv. | — |
| 2026-03-03 | Timothy C Dec | Senior Vice-President & CFO | A | +3,000 deriv. | — |
| 2026-02-26 | Jonathan Rubin | SVP, Chief Medical Officer | MIXED | +575 | −$34.22K |
| 2026-02-26 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | +600 | −$32.95K |
| 2026-02-26 | Timothy C Dec | Senior Vice-President & CFO | MIXED | +1,221 | −$64.83K |
| 2026-02-26 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | +898 | −$49.52K |
| 2026-02-25 | Frederick M. Hudson | Director | A | +4,475 | — |
| 2026-02-25 | Georges Gemayel | Director | MIXED | +19,475 | +$194.70K |
| 2026-02-25 | Charles W Newhall III | Director | A | +4,475 | — |
| 2026-02-25 | Carrolee Barlow | Director | A | +4,475 | — |
| 2026-02-25 | Timothy C Dec | Senior Vice-President & CFO | MIXED | +2,256 | −$120.78K |
| 2026-02-25 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | +1,544 | −$80.69K |
| 2026-02-25 | Jonathan Rubin | SVP, Chief Medical Officer | MIXED | +1,482 | −$49.73K |
| 2026-02-25 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | +1,484 | −$83.76K |
| 2026-02-23 | Bethany Sensenig | Director | MIXED | — | −$228.26K |
| 2026-02-20 | Jonathan Rubin | SVP, Chief Medical Officer | A | — | — |
| 2026-02-20 | Frank Mottola | SVP, Chief Tech. Ops. Officer | A | — | — |
| 2026-02-20 | Charles W Newhall III | Director | A | +7,966 deriv. | — |
| 2026-02-20 | Timothy C Dec | Senior Vice-President & CFO | A | — | — |
| 2026-02-20 | Frederick M. Hudson | Director | A | +7,966 deriv. | — |
| 2026-02-20 | Georges Gemayel | Director | A | +7,966 deriv. | — |
| 2026-02-20 | Jack A. Khattar | President, CEO | A | +341,610 deriv. | — |
| 2026-02-20 | Carrolee Barlow | Director | A | +7,966 deriv. | — |
| 2026-02-20 | Bethany Sensenig | Director | A | +7,966 deriv. | — |
| 2026-02-20 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | A | — | — |
| 2026-01-12 | Frederick M. Hudson | Director | M | +15,000 | +$194.70K |
| 2025-12-22 | Frank Mottola | SVP, Chief Tech. Ops. Officer | MIXED | — | −$431.65K |
| 2025-12-19 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | MIXED | +790 | −$31.55K |
| 2025-11-24 | Charles W Newhall III | Director | M | +15,000 | +$194.70K |
| 2025-11-17 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | A | — | — |
| 2025-10-10 | Charles W Newhall III | Director | Sell | −25,000 | −$1.27M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Charles W Newhall III | Director | 6,365,369 | $260.53M |
| Jack A. Khattar | President, CEO | 2,229,093 | $91.24M |
| Frederick M. Hudson | Director | 60,413 | $2.47M |
| Georges Gemayel | Director | 28,159 | $1.15M |
| Carrolee Barlow | Director | 27,045 | $1.11M |
| Padmanabh P. Bhatt | Sr. VP of IP, CSO | 19,795 | $810.21K |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 19,544 | $799.94K |
| Jonathan Rubin | SVP, Chief Medical Officer | 14,342 | $587.02K |
| Timothy C Dec | Senior Vice-President & CFO | 9,129 | $373.65K |
| William Todd Horich | SVP, Commercial Operations | 4,439 | $181.69K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SUPN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.